Evaluation of the Safety and Effectiveness of Lastacaft® Ophthalmic Solution 0.25%(Alcaftadine) for the Prevention of Itching Associated with Allergic Conjunctivitis: A Postmarketing Surveillance Study in Korea

14/12/2016
02/07/2024
EU PAS number:
EUPAS16675
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Initial protocol

Protocol 229666-007 PMS Korea Amd 2 FINAL 28Aug2015 D1

English (399.6 KB - PDF) View document
Study results
Study results

Korean Lastacaft Abstract

English (38.61 KB - PDF) View document
Study report
Other information